Michielsens, Celia A. J.
Boers, Nadine
den Broeder, Nathan
Wenink, Mark H.
van der Maas, Aatke
Mahler, Elien A. M.
Mulder, Michelle L. M.
van der Heijde, Désirée
van den Hoogen, Frank H. J.
Verhoef, Lise M.
den Broeder, Alfons A.
Funding for this research was provided by:
ReumaNederland (17-3-303)
Article History
Received: 27 September 2019
Accepted: 16 December 2019
First Online: 15 January 2020
Ethics approval and consent to participate
: The study has received ethical review board approval (number NL66181.091.18), dated 26 June 2018. Ethics approval was obtained for all participating centres from the central Commissie Mensgebonden Onderzoek (committee of human research) CMO regio Arnhem Nijmegen, Radboud University Medical Center, PO Box 9101, 6500 HB, Nijmegen, The Netherlands. Patient informed consent will be obtained from all participants in the study, prior to inclusion. The trial is registered at Dutch Trial Register, NL6771, date 27 November 2018.
: Not applicable.
: DvdH has received the following consulting fees: AbbVie, Amgen, Astellas, AstraZeneca, BMS, Boehringer Ingelheim, Celgene, Cyxone, Daiichi, Eisai, Eli-Lilly, Galapagos, Gilead, Glaxo-Smith-Kline, Janssen, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi, Takeda, UCB Pharma, Director of Imaging Rheumatology bv. AdB has received congress invitations from Roche, Cellgene, Pfizer, Abbvie, Biogen, and expert witness fees from Boehringer, BMS, Amgen, Feseniu, Novartis. The other authors declare that they have no competing interests.